MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss available
to common...
-$40,194K
Interest income
$1,346K
Tonmya
$3,731K
Zembrace Symtouch
$2,930K
Tosymra
$217K
Operating loss
-$41,537K
Product revenue, net
$6,878K
Other expense, net
-$3K
Total operating
expenses
$48,415K
Selling general and
administrative
$28,624K
Research and development
$18,213K
Cost of sales
$1,578K
Back
Back
Income Statement
source: myfinsight.com
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)